310 results about "Glutamic acid" patented technology

The application relates to the technical field of beef cattle breeding, and particularly discloses a compound preparation for promoting the feed intake, daily weight gain and improving the meat quality of beef cattle and application thereof, which is prepared from the following components in percentage by volume: 40% of micro-ecological preparation, 30% of hawthorn, 10% of medicated leaven, 10% of malt, 5% of areca nut and 5% of dried tangerine or orange peel; the compound preparation is prepared from microorganisms and multiple natural Chinese herbal medicines in a specific and scientific matching ratio; experiments prove that the compound preparation can increase the feed intake of beef cattle by 11.33%, increase the daily weight gain by 16.16%, and significantly shorten the breeding cycle; meanwhile, the contents of aspartic acid, threonine, glutamic acid, alanine, valine, isoleucine, leucine, tyrosine, phenylalanine, lysine, arginine and proline in the muscle are significantly increased, the nutritional quality and flavor taste of beef are effectively improved, the preparation is natural, residue-free and side-effect-free, the preparation method is simple, the cost is low, and the preparation has extremely high practical value and popularization prospect.

The application provides an arginine mutant and application thereof in 1,4-butanediamine biosynthesis, and belongs to the field of bioengineering. Escherichia coli The mutant is obtained by site-directed mutagenesis of key site amino acid residues based on wild-type EcAdiA from strain The application improves the enzyme activity stability of arginine decarboxylase in neutral environment, improves the conversion rate and conversion speed of 1,4-butanediamine in neutral environment, and lays a foundation for high-efficiency biosynthesis of 1,4-butanediamine.

This invention relates to the fields of microbial genetic engineering and fermentation biomanufacturing technology, specifically disclosing a recombinant Corynebacterium glutamicum with high 5-aminolevulinic acid (ALA) production and its applications. Addressing the problems of existing strains such as crude enzyme activity regulation, inhibited cell growth, the need for external inhibitors, and low yield, this invention uses Corynebacterium glutamicum as a host and removes the gdhA gene without scarring to reduce precursor competitive metabolism. Site-directed mutations of the endogenous hemB gene (S288A, D128E, R231K) are performed to moderately reduce dehydratase activity. A high-expression plasmid pXMJ19-hemA containing the hemA gene from Rhodopsinus capsulatum is constructed and introduced into the modified strain to obtain a recombinant strain with optimized triple metabolism. This strain reduces product degradation without the need for external dehydratase inhibitors, does not affect cell growth, and achieves a yield up to 4.30 times higher than the control after 42 hours of fermentation, with ALA accumulation exceeding 8.9 g / L. The strain exhibits stable characteristics, the process is simple, and it has good industrial application value.

The present invention relates to a method for producing 1,4-butanediol using a 1,4-butanediol-producing microorganism. The method for producing 1,4-butanediol can efficiently produce 1,4-butanediol by culturing a microorganism that produces 1,4-butanediol from glutamic acid under optimal medium conditions.

The present invention relates to a cosmetic composition, advantageously an eco-biological cosmetic composition, comprising: - polyglutamic acid or a salt thereof; and - at least one peptide derivative represented by the general formula (I) in which: - R1 represents a hydrogen atom, an acyl radical or an acyloxy radical; and - R2 represents the side chain of an alpha-amino acid chosen from the group consisting of phenylalanine, glutamic acid, arginine, cysteine, methionine, histidine and tyrosine. The present invention also relates to the use of said cosmetic composition for combating skin redness and / or skin aging; to its use for preventing and / or combating cutaneous vascular hyperproliferation and / or cutaneous inflammation and / or rosacea; and to a method for selecting compounds suitable for preventing and / or combating these pathologies.

This invention belongs to the fields of biotechnology and genetic engineering, and relates to a dual-enzyme fusion protein resistant to hydrogen peroxide inhibition, a polynucleotide, an expression vector, and its applications. The dual-enzyme fusion protein is composed of a glutamate oxidase mutant, a catalase mutant, and a linker peptide; the amino acid sequences of the glutamate oxidase mutant and the catalase mutant are shown in SEQ ID NO. 2 and 4, respectively, in the sequence listing. This invention improves the performance of single enzymes through enzyme molecule modification, achieves spatial synergy through fusion protein design, and enables industrial application through a continuous reaction process; it fundamentally solves the problem of hydrogen peroxide's inhibition of glutamate oxidase products; and the fusion expression simultaneously improves the stability and reusability of the dual enzymes.

This invention relates to a pyridoxal phosphate-responsive biosensor and its application, belonging to the field of synthetic biology biosensor technology. This invention is the first to discover and identify the relationship between pyridoxal phosphate and Cgl1185-P. cgl2838 The transcriptional regulation and response relationship between these factors was investigated, and this relationship was used as the basis for constructing a biosensor responsive to pyridoxal. The transcription factor regulatory system Cgl1185-P derived from Corynebacterium glutamicum was used. cgl2838 A biosensor for the specific detection of pyridoxal phosphate was constructed by assembling a reporter gene as the main component onto a plasmid, enabling effective detection of pyridoxal phosphate concentrations in intracellular or culture environments. This biosensor possesses advantages such as clear structure, high sensitivity, and good host adaptability, and can be used for fermentation process monitoring, cofactor metabolism research, and screening of relevant strains, showing promising application prospects in the fields of cofactor concentration monitoring and metabolic regulation.

The application discloses a kind of genetic engineering escherichia coli plasmid expression culture medium and fermentation process, including basic medium and feed medium;The basic medium includes glycerol, yeast hydrolysate, yeast peptone, L-glutamic acid, L-valine, L-isoleucine, arginine, tyrosine, lysine, proline, glycine, ammonium sulfate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, citric acid, magnesium sulfate, ferrous sulfate, zinc sulfate, calcium chloride, manganese chloride, cobalt chloride, copper chloride, sodium ethylenediaminetetraacetate;Feed medium includes glycerol, citric acid, magnesium sulfate, ferrous sulfate, zinc sulfate, calcium chloride, manganese chloride, cobalt chloride, copper chloride, sodium ethylenediaminetetraacetate.The application inhibits the accumulation of harmful metabolites, and creates the optimal intracellular environment for stable replication of plasmid.In industrial fermentation scale, the amount of plasmid harvested per liter of fermentation broth is more than 1 gram, and the supercoiling ratio of plasmid DNA is stably maintained at more than 90%, with minimal batch-to-batch variation.

This invention belongs to the field of biomedical technology and provides a polypeptide with ATG8 protein binding activity, comprising the following structure: X1-X2-X3-X4-X5-X6-X7; wherein: X1, X2, and X3 are independently selected from glutamic acid or are absent; X4 is selected from tryptophan, phenylalanine, or leucine; X5 is valine; X6 is selected from leucine, isoleucine, or valine; and X7 is selected from valine, tryptophan, phenylalanine, or tyrosine. Compared with existing autophagy inhibitors, this polypeptide has the following superior pharmacokinetic potential and development flexibility in terms of target selection, binding strength, and mechanism of action: the short sequence not only reduces synthesis costs but also leaves more room for modification, which is expected to significantly improve the metabolic stability and drug-likeness potential of the polypeptide; it can serve as a highly efficient ATG8 targeting ligand and can be widely used in the construction of biochemical probes, screening of PPI competitive inhibitors, and the development of targeted delivery systems.

This invention provides a strain derived from Clostridium difficile (Clostridium difficile) Clostridioides difficile This invention relates to mutants of glutamate dehydrogenase and their preparation, including single-site, two-site, or multi-site mutants. The invention effectively solves the problems of inactivity or low activity of glutamate dehydrogenase in the biocatalytic transformation of 2-carbonyl-4-(hydroxymethylphosphono)butyric acid as a substrate, and provides a continuous chemical method for the synthesis of 2-carbonyl-4-(hydroxymethylphosphono)butyric acid using a microchannel reactor throughout the entire process.

This invention provides an oil-purifying cleansing mud and its preparation method. The cleansing mud, by weight, comprises 1-5 parts of a viscosity modifier, 0.01-0.1 parts of a chelating agent, 10-20 parts of a moisturizer, 15-25 parts of a surfactant, 0.1-1 parts of a thickener, 0.1-5 parts of a cleanser, 0.1-2 parts of an antioxidant, 0.1-1 parts of a fragrance, and 50-75 parts of water. The surfactant is a combination of sodium cocoyl glycinate, lauryl hydroxysulfonate betaine, cocoyl glutamic acid, decyl glucoside, potassium cocoyl glycinate, and cetearyl alcohol polyether-25. This oil-purifying cleansing mud, through the use of surfactants, cleansers, and moisturizers, gently cleanses pores, absorbs oil and dirt, and simultaneously soothes the skin, preventing dryness and tightness. The synergistic combination of these components achieves a balance between cleansing, oil removal, and gentleness, precisely regulating the skin's balance and thus enhancing the consumer experience.

The application discloses a prenylated polyketide compound, a preparation method and application thereof, and the prenylated polyketide compound is separated from rice fermented with Xylaria nigriplicata. The neuroprotective effect of the prenylated polyketide compound on glutamate-induced excitotoxicity of PC12 cells is clarified through comprehensive evaluation of cell viability, apoptosis and key oxidative stress markers.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to clofazimine-organic acid co-crystals, a preparation method and application thereof. The clofazimine-organic acid co-crystal is one of clofazimine-ferulic acid monohydrate co-crystal, clofazimine-ferulic acid co-crystal, clofazimine-glutaric acid co-crystal, clofazimine-glycolic acid co-crystal (CFZ-GA 1:1), clofazimine-glycolic acid co-crystal (CFZ-GA 1:1.5), clofazimine-salicylic acid co-crystal, clofazimine-L-aspartic acid co-crystal, clofazimine-L-pyroglutamic acid co-crystal, clofazimine-gallic acid co-crystal, clofazimine-succinic acid co-crystal, clofazimine-tartaric acid co-crystal and clofazimine-DL-mandelic acid co-crystal. The clofazimine-organic acid co-crystal provided by the application significantly improves the solubility and fluidity of clofazimine, thereby improving the bioavailability of clofazimine, and has a broad medicinal prospect.

This invention relates to a method for preparing rice saccharification liquid, dough for baking products, and baked goods. More specifically, it relates to a baked goods comprising rice saccharification liquid prepared using yellow koji, white koji, and sake lees, and a method for preparing the same. This invention develops a rice saccharification liquid prepared using yellow koji, white koji, and sake lees, which, compared to existing rice saccharification liquids prepared using yellow koji or white koji, exhibits reduced sweetness and increased glutamic acid and aspartic acid content to provide further enhanced umami, in addition to enhancing various rich flavors (aromas). Furthermore, by adding the rice saccharification liquid of this invention, baked goods with umami and various rich flavors (aromas) can be prepared.

Provided is a cyclic peptide, which has a sequence of cyclo(X1X2X3X4X5X6), wherein X1 is asparagine; X2 is glycine or sarcosine; X3 is arginine; X4 is selected from a group consisting of threonine, tyrosine, and phenylalanine; X5 is lysine; and X6 is selected from a group consisting of tyrosine, valine, and glutamic acid. Provided is a preparation method for the cyclic peptide. Provided is a complex, comprising the cyclic peptide, a linker, and a chelating agent. Provided is a use of the complex as a radionuclide-labeled targeting molecule. Provided is a radionuclide labeling method, comprising bringing a complex that chelates a radionuclide into contact with an object to be labeled by the radionuclide.

The application belongs to the technical field of vinegar brewing, and provides a compound koji inoculated with indigenous Aspergillus oryzae and Aspergillus niger and a method for strengthening Shanxi old mature vinegar. Indigenous Aspergillus oryzae CGMCC 42103 with high yield of acid protease and glutaminease and Aspergillus niger CGMCC 15672 with high yield of saccharifying enzyme are mixed and inoculated in bran and soybean powder medium to prepare compound koji, and the prepared compound koji is applied to the fermentation process of Shanxi old mature vinegar to prepare new vinegar, the total acid, amino acid nitrogen, non-volatile acid and glutamic acid content of the new vinegar are 6.18 g / 100 mL, 0.38 g / 100 mL, 2.45 g / 100 mL and 58.83 mg / 100 mL respectively, compared with the comparative example in which only highland millet with a mass fraction of 60% is added in the alcohol fermentation stage to carry out conventional fermentation of food vinegar, the new vinegar is improved by 20.47%, 153.33%, 33.15% and 118.86% respectively, and the content of organic acid and volatile aroma components is enriched.

This invention discloses a method for the efficient synthesis of gastrodin using recombinant Corynebacterium glutamicum, belonging to the fields of genetic engineering, fermentation engineering, and synthetic biology. This invention uses Corynebacterium glutamicum as the host bacterium and knocks out… pobA The gene was expressed, and the engineered strain WN01 / pB6 was constructed using the expression plasmid pEC-XK99E to express cladoid-pyruvate lyase, carboxylic acid reductase, and glycosyltransferase, achieving heterologous synthesis of gastrodin. Further overexpression was then performed. aroG Genes, overexpression of protein-coding genes that activate carboxylic acid reductase sfp The engineered strain WN05 / pB6 was able to synthesize 7.37 g / L of gastrodin at the shake flask level, and the gastrodin yield reached 17.77 g / L at 72 h of batch fermentation in a 5-L fermenter, with a yield of 0.247 g / L / h. This provides a brand-new biomanufacturing platform for the industrial production of gastrodin.

This invention provides a cultivation method to enhance the medicinal efficacy of Paris polyphylla, relating to the field of Paris polyphylla cultivation and management technology. The cultivation method mainly involves the combined application of a foliar fertilizer prepared from potassium dihydrogen phosphate, compound amino acids, potassium lauroyl glutamate, and pomegranate peel fermentation extract, and a plant compound fertilizer prepared from straw and manure compost, pomegranate peel fermentation material, and superphosphate. This invention overcomes the shortcomings of existing technologies, effectively ensuring the normal growth of Paris polyphylla while increasing the content of Paris saponins in its rhizomes, thus comprehensively improving the economic benefits of cultivation.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for distinguishing hypertrophic cardiomyopathy and left ventricular hypertrophy and application. The application analyzes the metabolome of hypertrophic cardiomyopathy (HCM) patients, left ventricular hypertrophy (LVH) patients caused by non-hypertrophic cardiomyopathy and healthy people, finds that carnitine C16:2, carnitine C14:0, carnitine C16:0, carnitine C18:0 and carnitine C18:1 are differentially expressed in HCM patients and LVH patients, pyridoxine phosphate, ito acid, adenosine monophosphate, adenosine diphosphate and adenosine triphosphate are differentially expressed in HCM patients and healthy people, lysine base, methyl glutamic acid, acetyl proline, malate semialdehyde and citramalate are differentially expressed in LVH patients and healthy people, and ROC curve analysis shows excellent prediction effect, strong specificity and high sensitivity.

This invention provides a cell microenvironment stabilizer that captures hydrogen ions, its preparation method, and its application, belonging to the field of biomedical technology. The preparation method of this cell microenvironment stabilizer includes the following steps: (1) mineralizing CaCl2 with TGF-β1, catalase, and polyethylene glycol-polyglutamic acid block copolymer to obtain mineralized nanoparticles; (2) preparing hydrogel microspheres under freezing conditions using a microfluidic device, and then photocrosslinking the frozen hydrogel microspheres; (3) mixing the hydrogel microspheres with the mineralized nanoparticles to prepare the cell microenvironment stabilizer. This invention prepares a mineralized hydrogel microsphere, which, as a cell microenvironment stabilizer, can be used to block the NLRP3 cascade in chronic inflammation, capturing excess hydrogen ions through the mineralization layer to neutralize the acidic microenvironment. This micro / nano bioreactor based on hydrogel microspheres can effectively interfere with NLRP3 in the microenvironment of degenerated tissues from inside and outside the cells, inhibiting chronic inflammation.

The application discloses application of Fagopyrum cymosum root powder in preparation of products for improving egg quality or intestinal health of laying ducks, and belongs to the technical field of feed additives. The application provides application of Fagopyrum cymosum root powder in preparation of products for improving egg quality or intestinal health of laying ducks, and the Fagopyrum cymosum root powder can improve eggshell strength, yolk color and eggshell proportion, improve the content of aspartic acid, threonine, glutamic acid, glycine, cystine and leucine in yolk, improve the content of arachidonic acid and arachidonic acid in yolk, and reduce the content of saturated fatty acid in yolk; the Fagopyrum cymosum root powder can improve the activity of maltase in the mucous membrane of the jejunum of laying ducks, and can improve the diversity and abundance of intestinal flora of laying ducks. The application provides a new strategy for improving egg quality or intestinal health of laying ducks.

This invention provides a novel raw material that, for cats, which exhibit unique characteristics in their kidneys compared to other mammals, can inhibit the decline in feline kidney function and improve coat condition while maintaining the form of cat food or other feeds. When using a poorly soluble soybean protein raw material with a characteristic amino acid composition of less than a glutamic acid (Glu) to leucine (Leu) mass ratio of 2, and an NSI of 10%–60%, the decline in feline kidney function can be inhibited and coat condition improved through small-scale intake. This raw material can also be obtained as undigested residue from the soybean peptide manufacturing process.

This invention discloses a mutant, gene, and recombinant bacteria of a highly thermostable single-chain sweet protein. The mutant is characterized by the following amino acid sequences shown in SEQ ID NO.1: isoleucine (I) at position 5 is mutated to glutamic acid (E), glutamic acid (E) at position 23 is mutated to alanine (A), isoleucine (I) at position 26 is mutated to arginine (R), cysteine ​​(C) at position 41 is mutated to alanine (A), tyrosine (Y) at position 65 is mutated to isoleucine (I), glycine (G) at position 83 is mutated to arginine (R), and asparagine (N) at position 90 is mutated to glutamic acid (E). Based on structural analysis and computationally assisted design for protein stability, this invention achieves site-directed mutagenesis of the single-chain sweet protein, resulting in a highly thermostable mutant. Compared to the original single-chain sweet protein, the thermostable mutant of this invention exhibits higher T... m It was heated by more than 20.4°C while maintaining its sweetness.

The present disclosure encompasses solid state forms of Lucerastat, in embodiments crystalline Lucerastat: L-Pyroglutamic acid, crystalline Lucerastat: Salicylic acid, crystalline Lucerastat: Fumaric acid, crystalline Lucerastat: Benzoic acid and crystalline Lucerastat: o-Acetylsalicylic acid, solid state form thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

This invention provides an engineered bacterium for producing ectoine, its preparation method, and its application. The engineered bacterium is prepared using a method comprising the following steps: using *Corynebacterium glutamicum* as the starting strain, feedback inhibition by aspartate kinase LysC is relieved, the activity of the gene lysE encoding lysine efflux permease is reduced, and the ectoine synthesis gene cluster ectABC is expressed. Based on this, the activity of any one or at least two of the following—diaminobutyrate acetyltransferase EctA, pyruvate carboxylase Pyc, or aspartate kinase LysC—is enhanced, and / or the activity of any one or at least two of the following—maloquinone oxidoreductase Mqo or homoserine dehydrogenase Hom—is reduced to further increase ectoine yield.

The present invention relates to a Corynebacterium sp. mutant microorganism producing L-glutamic acid and a method of producing L-glutamic acid using the same, and more specifically, to a novel NADP-dependent malic enzyme variant involved in the L-glutamic acid biosynthetic pathway, a polynucleotide, and a transformant, as well as a method of producing L-glutamic acid using the same. The NADP-dependent malic enzyme variant according to the present invention is obtained by substituting one or more amino acids in the amino acid sequence constituting NADP-dependent malic enzyme to change the enzymatic activity of the NADP-dependent malic enzyme, and a recombinant microorganism comprising the NADP-dependent malic enzyme variant is capable of efficiently producing L-glutamic acid.

The present invention relates to a Corynebacterium sp. mutant microorganism producing L-glutamic acid and a method of producing L-glutamic acid using the same, and more specifically, to a novel malate:quinone oxidoreductase variant involved in the L-glutamic acid biosynthetic pathway, a polynucleotide, and a transformant, as well as a method of producing L-glutamic acid using the same. The malate:quinone oxidoreductase variant according to the present invention is obtained by substituting one or more amino acids in the amino acid sequence constituting malate:quinone oxidoreductase to change the enzymatic activity of the malate:quinone oxidoreductase, and a recombinant microorganism comprising the malate:quinone oxidoreductase variant is capable of efficiently producing L-glutamic acid.

The present invention relates to a test kit for performing an assay to detect and measure at least one autoantibody molecule in a subject developing type 1 diabetes (T1D). The invention more specifically relates to a recombinant antigen molecule fused to a bioluminescent reporter protein to detect an autoantibody molecule against a self-antigen. Said self-antigen is preferably expressed by pancreatic islet beta cells and include insulin, proinsulin, Glutamate decarboxylase 65, islet antigen 2, and Zinc transporter 8. More specifically, the present invention relates to an assay comprising a set of at least three recombinant antigen molecules in a single composition, the antigen molecules being selected from the list comprising recombinant human Glutamate decarboxylase 65, recombinant human islet antigen 2, recombinant human Zinc transporter 8, recombinant human insulin, and recombinant human proinsulin. The invention further relates to methods for determining the presence and / or level of at least one autoantibody molecule in a sample from a human subject developing T1D using said recombinant antigen molecules. According to the invention, the presence, absence, or amount of one or more autoantibody molecules against said self-antigens is determined with a luciferase immune precipitation system (LIPS) assay or a modified version of a LIPS assay, i.e., a solid phase capture LIPS (scLIPS) assay.